Cargando…

687. Zinplava Expert Retrospective Observations (ZERO) Study Findings on Clostridioides difficile Recurrence

BACKGROUND: Describe real world experience in the use of bezlotoxumab (BZT) for the prevention of recurrent Clostridioides difficile(CDI) infection with a 1 year follow up following administration. The original BZT studies showed approximately 16% rate of recurrence at 12 weeks with other baseline a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobs, Micah, Morris, Sharon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678254/ http://dx.doi.org/10.1093/ofid/ofad500.749

Ejemplares similares

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

400. Rehospitalization of Patients for Recurrent Clostridioides difficile Infection
por: Drwiega, Emily, et al.
Publicado: (2022)

390. Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection
por: Morrison, Austin R, et al.
Publicado: (2022)

793. Expert Panel Consensus Ranking of Comorbid Conditions Causally Related to Clostridioides difficile Infection
por: Goodman, Katherine E, et al.
Publicado: (2020)

687. Iatrogenic Kaposi’s Sarcoma Following Treatment with Vedolizumab
por: Ajao, Susanne O, et al.
Publicado: (2020)

789. Evaluation of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence
por: Johnson, Tanner M, et al.
Publicado: (2020)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

2407. Overexpression of Virulence Factors in Biofilm from Recurrent Clostridium (Clostridioides) difficile Infection Isolates.
por: Tijerina, Laura, et al.
Publicado: (2019)

389. Epidemiology of Multiple Recurrent Clostridioides difficile in the Atlanta Metropolitan Area between 2016 and 2019
por: Fridkin, Scott, et al.
Publicado: (2022)

658. Oral Vancomycin Taper for First Occurrence of Clostridioides difficile Compared to Standard of Care: An Observational Retrospective Matched Cohort Study
por: Moore, Sarah E, et al.
Publicado: (2023)

2413. Assessment of compliance with Clostridioides difficile prophylaxis guideline and its efficacy on secondary prophylaxis and reducing hospital-onset Clostridioides difficile infections.
por: Vyas, Nikunj M, et al.
Publicado: (2019)

792. Evaluation of Persistent Diarrhea and Recurrence Following Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
por: Boton, Noah, et al.
Publicado: (2020)

471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh
por: Sofjan, Amelia K, et al.
Publicado: (2018)

2387. Learning the Influence of Individual Clostridioides difficile Infections
por: Mu, Emily, et al.
Publicado: (2019)

2347. Impact of Multidisciplinary Review of Clostridioides difficile Testing
por: Foreman, Jena, et al.
Publicado: (2019)

729. Real World Efficacy of Bezlotoxumab for Prevention of Clostridioides Difficile Recurrence in Immunosuppressed Patients
por: Perreault, Sarah, et al.
Publicado: (2020)

2382. Recurrent Clostridioides difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life
por: Garey, Kevin W, et al.
Publicado: (2019)

2565. Initial and Recurrent Episodes of Clostridioides difficile: Online Education as a Tool to Improve Management Strategies
por: Hurst, Simi Thomas, et al.
Publicado: (2019)

2432. Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Saha, Srishti, et al.
Publicado: (2019)

657. Impact of Oral Vancomycin Duration on Clostridioides difficile Recurrence in Patients Requiring Concurrent Systemic Antibiotics
por: Marsh, Kassandra, et al.
Publicado: (2023)

71. Diagnostic Stewardship of Clostridioides difficile Testing
por: Qamar, Zahra, et al.
Publicado: (2021)

Gut metabolites predict Clostridioides difficile recurrence
por: Dawkins, Jennifer J., et al.
Publicado: (2022)

2394. Different Clostridioides difficile Ribotypes Among Patients With Colonization, Initial Clinical Disease, and Recurrent Clinical Disease
por: Khoury, Kevin, et al.
Publicado: (2018)

1496. Bezlotoxumab Administered at the End of a Suppressive Drug Regimen for Patients with Multiply Recurrent Clostridioides difficile Infection
por: Tan, Xing, et al.
Publicado: (2019)

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
por: Tillotson, Glenn S, et al.
Publicado: (2022)

684. Characteristics of Patients with Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences
por: Guh, Alice, et al.
Publicado: (2023)

2672. Clostridioides difficile Infection Among Bone Marrow Transplant Recipients: Findings From a Single Institution
por: Thomas, Christine, et al.
Publicado: (2019)

529. Overdiagnosis of Clostridioides difficile with a Multiplex PCR Panel
por: Arora, Vaneet, et al.
Publicado: (2018)

2404. Molecular Epidemiology of Clostridioides difficile in the United States, 2017
por: Paulick, Ashley, et al.
Publicado: (2019)

2235. Fecal Biomarkers for Clostridioides difficile Infection in Cancer Patients
por: Olvera, Adilene, et al.
Publicado: (2019)

381. Antibiotic Spectrum Index and Risk of Clostridioides difficile Infection
por: Ray, Michael J, et al.
Publicado: (2022)

P18 Audit on compliance with the preventive measures on Clostridioides difficile
por: Marques Reis, I, et al.
Publicado: (2023)

707. Molecular Epidemiology of Clostridioides difficile Colonization in Families with Infants
por: Toltzis, Philip, et al.
Publicado: (2023)

2351. Rate and Consequences of Missed Clostridioides (Clostridium) difficile Infection Diagnosis from Non-disclosure of Clostridioides difficile Multiplex PCR Results. Two-Hospital Experience
por: Zacharioudakis, Ioannis, et al.
Publicado: (2019)

687. Modeling the Impact of Introduction of Influenza Vaccination on ILI Cumulative Case Count in Cameroon
por: Tamoufe, Ubald, et al.
Publicado: (2018)

687. In vitro Activity of a New Generation Oxopyrazole Antibiotic Against Acinetobacter spp.
por: Goldberg, Joel, et al.
Publicado: (2019)

2367. Selecting Testing Frequency for Estimation of Incubation Periods: A Simulation Study Based on Clostridioides difficile Observations
por: Wilson, Brigid, et al.
Publicado: (2019)

2421. Efficacy of Secondary Prophylaxis with Oral Vancomycin in Preventing Recurrent Clostridioides difficile Infections in Patients Receiving Systemic Antibiotics
por: Pillinger, Kelly E, et al.
Publicado: (2019)

2412. Oral Vancomycin Prophylaxis Against Recurrent Clostridioides difficile Infection: Efficacy and Side-effects: Two Hospitals Experience
por: Zacharioudakis, Ioannis, et al.
Publicado: (2019)

2374. Healthcare Resource Use, Costs, and Recurrences in Patients with Clostridioides difficile Infection: A Real-world Data Analysis
por: Nelson, Winnie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_k1irfqddvhqb20un5or80vuith